Imaging for Cancer: CT, MRI, PET, and Ultrasound

Medical imaging is a foundational pillar of cancer diagnosis, staging, treatment planning, and surveillance. Four modalities dominate oncology practice — computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound — each with distinct physical principles, clinical strengths, and recognized limitations. Understanding how these tools differ, when each is appropriate, and what regulatory and safety frameworks govern their use is essential context for anyone navigating a cancer evaluation or exploring oncology broadly.

Definition and scope

Cancer imaging encompasses any non-invasive or minimally invasive technique that produces visual representations of internal anatomy or metabolic activity to detect, characterize, or monitor tumors. In the United States, diagnostic imaging equipment is regulated as a medical device under the Food, Drug, and Cosmetic Act; the Food and Drug Administration (FDA) classifies CT scanners under 21 CFR Part 892 and MRI systems under the same part. Radiation-emitting devices, including CT and PET scanners, also fall under FDA's Center for Devices and Radiological Health (CDRH) oversight.

The four primary oncologic imaging modalities occupy distinct positions:

• CT (Computed Tomography): Cross-sectional X-ray imaging reconstructed by computer algorithms; produces detailed anatomic maps.
• MRI (Magnetic Resonance Imaging): Uses strong magnetic fields and radiofrequency pulses; excels at soft-tissue contrast without ionizing radiation.
• PET (Positron Emission Tomography): Detects metabolically active tissue through radiolabeled tracers, most commonly fluorodeoxyglucose (FDG); typically fused with CT (PET/CT) for anatomic localization.
• Ultrasound: Uses high-frequency sound waves reflected off tissue boundaries; real-time, portable, and free of ionizing radiation.

Each modality feeds into downstream decisions including cancer staging and grading, biopsy targeting, surgical planning, and response assessment.

How it works

Computed Tomography

A CT scanner rotates an X-ray tube and detector array around the patient, acquiring hundreds of projections that software reconstructs into axial, coronal, and sagittal slices. Intravenous iodinated contrast agents enhance vascular structures and alter tissue attenuation to improve lesion conspicuity. Spatial resolution of modern multidetector CT systems reaches approximately 0.5–0.6 mm in-plane, making CT the standard for chest, abdomen, and pelvis staging. The primary safety consideration is ionizing radiation exposure; the American College of Radiology (ACR) and the Radiological Society of North America (RSNA) jointly promote the Image Wisely program to reduce unnecessary radiation dose in adult imaging.

Magnetic Resonance Imaging

MRI exploits the magnetic properties of hydrogen nuclei. A strong external field aligns protons; radiofrequency pulses perturb that alignment; the emitted signal during relaxation is spatially encoded to form images. T1 and T2 weighting reveal different tissue characteristics — fat appears bright on T1, fluid bright on T2. Gadolinium-based contrast agents (GBCAs) can identify blood-brain barrier disruption, tumor vascularity, and lymph node involvement. MRI carries no ionizing radiation but requires screening for ferromagnetic implants; the American College of Radiology publishes a Manual on MR Safety that defines Zone I through Zone IV restricted areas and implant compatibility standards.

PET and PET/CT

FDG-PET exploits the Warburg effect — many malignant cells consume glucose at elevated rates. After intravenous injection of FDG (a glucose analog tagged with fluorine-18, half-life approximately 110 minutes), a gamma camera detects annihilation photons produced when positrons collide with electrons. Fusing PET data with a contemporaneous low-dose CT provides metabolic and anatomic information in a single session. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) publishes procedure standards covering patient preparation, dosing, and acquisition protocols.

Ultrasound

Transducers emit pulses of sound at frequencies between 2 and 18 MHz and record echo return times to construct real-time images. Doppler modes measure blood flow velocity within vessels and tumors. Contrast-enhanced ultrasound (CEUS) uses microbubble agents approved by the FDA for specific hepatic indications. Elastography, an advanced ultrasound technique, measures tissue stiffness — stiffer nodules raise suspicion for malignancy in thyroid and breast imaging.

Common scenarios

Oncology imaging is deployed across five discrete phases of cancer care:

1. Detection and screening — Low-dose CT (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) for annual lung cancer screening in adults aged 50–80 with a 20 pack-year smoking history (USPSTF Lung Cancer Recommendation, 2021). Mammography (X-ray based, distinct from CT) and ultrasound complement each other in breast evaluation.
2. Diagnosis and characterization — MRI is preferred for brain, spine, liver, and pelvic tumors because of superior soft-tissue contrast. CT guides core needle biopsies of thoracic and abdominal masses.
3. Staging — PET/CT is the standard of care for staging Hodgkin lymphoma, non-small cell lung cancer, and head and neck cancers. CT of chest, abdomen, and pelvis remains standard for colorectal cancer staging.
4. Treatment planning — Radiation oncologists use CT simulation to delineate target volumes; MRI-guided linear accelerators (MR-Linac systems) allow real-time soft-tissue visualization during beam delivery.
5. Response assessment and surveillance — The Lugano Classification uses PET/CT with Deauville scores (a 5-point scale) to assess lymphoma response. Pathology reports interpret biopsy material obtained after imaging identifies a suspicious lesion.

Decision boundaries

Choosing the correct modality involves weighing sensitivity, specificity, radiation exposure, cost, contraindications, and clinical question. The table below summarizes primary decision factors:

CT vs. MRI is the most common comparison in oncology. CT is faster (a chest-abdomen-pelvis scan completes in under 2 minutes on modern equipment), more widely available, and better for lung parenchyma and cortical bone. MRI requires 20–60 minutes per exam, cannot be used in patients with non-MRI-conditional cardiac pacemakers, and is more expensive — Medicare reimbursement rates for brain MRI without and with contrast are set in the CMS Physician Fee Schedule, which is updated annually.

PET/CT adds cost and radiation but changes management in a clinically meaningful proportion of patients with aggressive lymphomas and lung cancers; institutional protocols govern when PET adds sufficient information to justify those tradeoffs. The regulatory context governing oncology diagnostics, including FDA device approvals and CMS coverage determinations, shapes which indications receive reimbursement.

Ultrasound fills a critical role where speed, portability, and absence of radiation outweigh resolution limits — thyroid nodule evaluation, testicular masses, and guidance for superficial biopsies represent core applications. The ACR Thyroid Imaging Reporting and Data System (TI-RADS) standardizes ultrasound characterization of thyroid nodules into five risk categories, directly linking imaging features to biopsy thresholds.

References

• U.S. Food and Drug Administration — Center for Devices and Radiological Health (CDRH)
• 21 CFR Part 892 — Radiology Devices (eCFR)
• American College of Radiology — MR Safety
• ACR — Image Wisely (adult radiation safety program)
• Society of Nuclear Medicine and Molecular Imaging — Procedure Standards
• U.S. Preventive Services Task Force — Lung Cancer Screening (2021)
• Centers for Medicare & Medicaid Services — Physician Fee Schedule
• [ACR TI-RADS — Thyroid Imaging Reporting and Data System](https://www.ac

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)